Suppr超能文献

评估暑假对接受雷珠单抗治疗的年龄相关性黄斑变性(AMD)患者视力的影响。

Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.

作者信息

Massamba N, Dirani A, Knoeri J, Pasquier B, Ingram A, Soubrane G

机构信息

Department of Ophthalmology, Cergy Pontoise Hospital, Paris, France.

Department of Ophthalmology, CHUV, Lausanne, Switzerland.

出版信息

Eye (Lond). 2015 Nov;29(11):1453-7. doi: 10.1038/eye.2015.128. Epub 2015 Jul 24.

Abstract

PURPOSE

To evaluate the impact of traditional French summer vacation on visual acuity and spectral domain-optical coherence tomography (SD-OCT) of Wet AMD patients being treated with intravitreal Ranibizumab.

METHODS

This was a consecutive, comparative, single-centre, prospective analysis. All patients who were being treated with intravitreal injection of 0.5 mg ranibizumab at Cergy Pontoise Hospital, Department of Ophthalmology between July 2013 and September 2014 were included. Patients were divided into two groups: (A) patients who skipped one ranibizumab intravitreal injection during holidays, and (B) patients who received injection during their holidays. Evaluations occurred prior to traditional holiday (baseline) and 2 months later, consisting of BCVA using ETDRS, and a complete ophthalmic examination that included slit-lamp biomicroscopy, fundus examination, fluorescein angiography (FA), indocyanine green angiography (ICGA), and spectral domain-optical coherence tomography (SD-OCT). All patients were being treated with PRN anti-VEGF regimen and criteria for reinjection included a visual acuity loss >5 ETDRS letters and/or an increase of central retinal thickness, presence of subretinal fluid, intraretinal fluid, or pigment epithelium detachment. If reinjection criteria were not met, patients were advised to return in 4 weeks.

RESULTS

The mean visual acuity change was -0.071 ± 0.149 (LogMAR) in group A and + 0.003 ± 0.178 in group B (P = 0.041). At the second visit (2 months after preholidays visit), 61.8% of patients in group A had SRF and/or intraretinal cysts, and only 27.6% of patients in group B. There was a significant difference in the persistence of fluid between the two groups (P = 0.007, χ(2)-test).

CONCLUSION

This cases series demonstrated the detrimental impact of holidays on visual acuity in patients treated with ranibizumab for AMD, which, in spite of their treatment regimen, still leave in vacation. Therefore, it is important to convey the message of treatment adherence to patients, despite their need of holidays.

摘要

目的

评估传统法国夏季度假对接受玻璃体内注射兰尼单抗治疗的湿性年龄相关性黄斑变性(Wet AMD)患者视力及光谱域光学相干断层扫描(SD - OCT)的影响。

方法

这是一项连续、对比、单中心的前瞻性分析。纳入2013年7月至2014年9月间在塞尔吉 - 蓬图瓦兹医院眼科接受0.5毫克兰尼单抗玻璃体内注射治疗的所有患者。患者分为两组:(A)假期期间跳过一次兰尼单抗玻璃体内注射的患者,以及(B)假期期间接受注射的患者。评估在传统假期前(基线)及2个月后进行,包括使用ETDRS的最佳矫正视力(BCVA),以及包括裂隙灯生物显微镜检查、眼底检查、荧光素血管造影(FA)、吲哚菁绿血管造影(ICGA)和光谱域光学相干断层扫描(SD - OCT)的完整眼科检查。所有患者均接受按需抗血管内皮生长因子(anti - VEGF)治疗方案,再次注射的标准包括视力下降>5个ETDRS字母和/或中心视网膜厚度增加、存在视网膜下液、视网膜内液或色素上皮脱离。如果未达到再次注射标准,建议患者4周后复诊。

结果

A组平均视力变化为-0.071±0.149(LogMAR),B组为+0.003±0.178(P = 0.041)。在第二次就诊时(假期前就诊后2个月),A组61.8%的患者有视网膜下液(SRF)和/或视网膜内囊肿,而B组仅为27.6%。两组间液体持续存在情况有显著差异(P = 0.007,χ²检验)。

结论

该病例系列证明了假期对接受兰尼单抗治疗AMD患者视力的有害影响,尽管有治疗方案,但患者在度假期间仍会受到影响。因此,尽管患者需要度假,但向他们传达坚持治疗的信息很重要。

相似文献

1
Evaluating the impact of summer vacation on the visual acuity of AMD patients treated with ranibizumab.
Eye (Lond). 2015 Nov;29(11):1453-7. doi: 10.1038/eye.2015.128. Epub 2015 Jul 24.
3
Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Am J Ophthalmol. 2016 Sep;169:95-103. doi: 10.1016/j.ajo.2016.06.021. Epub 2016 Jun 16.
4
Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.
9
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.
Eye (Lond). 2016 Aug;30(8):1077-83. doi: 10.1038/eye.2016.95. Epub 2016 May 27.

引用本文的文献

2
Reasons for Delayed Anti-VEGF Treatment During COVID-19 Lockdown and Clinical Impact in Neovascular Age-Related Macular Degeneration.
Ophthalmol Ther. 2023 Oct;12(5):2537-2555. doi: 10.1007/s40123-023-00757-2. Epub 2023 Jul 4.
6
[Adherence to anti-VEGF treatment-Considerations and practical recommendations].
Ophthalmologe. 2021 Aug;118(8):801-809. doi: 10.1007/s00347-020-01273-5. Epub 2020 Dec 3.
8
The Impact of COVID-19 on Intravitreal Injection Compliance.
SN Compr Clin Med. 2020;2(12):2546-2549. doi: 10.1007/s42399-020-00614-4. Epub 2020 Oct 28.

本文引用的文献

1
Rate of vision loss in neovascular age-related macular degeneration explored.
Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1859-65. doi: 10.1007/s00417-014-2885-y. Epub 2014 Dec 11.
2
Adherence barriers to chronic dialysis in the United States.
J Am Soc Nephrol. 2014 Nov;25(11):2642-8. doi: 10.1681/ASN.2013111160. Epub 2014 Apr 24.
3
Self-management activities in diabetes care: a systematic review.
Aust Health Rev. 2013 Sep;37(4):513-22. doi: 10.1071/AH13060.
4
Patterns of nonadherence to antihypertensive therapy in primary care.
J Clin Hypertens (Greenwich). 2013 Feb;15(2):107-11. doi: 10.1111/jch.12030. Epub 2012 Oct 26.
5
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
7
Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity.
Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):633-7. doi: 10.1007/s00417-010-1520-9. Epub 2010 Sep 24.
8
A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Am J Ophthalmol. 2009 Jul;148(1):43-58.e1. doi: 10.1016/j.ajo.2009.01.024. Epub 2009 Apr 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验